Combination of inhibitors for two glycolytic enzymes portrays high synergistic efficacy against Cryptosporidium parvum
Antimicrobial Agents and Chemotherapy · 2023
DOI: 10.1128/aac.00569-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Shahbaz M Khan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathobiology, College of Veterinary Medicine, University of Illinois Urbana-Champaign , Urbana, Illinois, USA. Hauptthemen laut MEDLINE: Cryptosporidiosis, Cryptosporidium parvum, Cryptosporidium. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Agriculture.
Abstract (Originalsprache)
Cryptosporidium is an intracellular protozoan parasite that causes serious enteric disease in humans and in a wide range of animals worldwide. Despite its high prevalence, no effective therapeutic drugs are available against life-threatening cryptosporidiosis in at-risk populations including malnourished children, immunocompromised patients, and neonatal calves. Thus, new efficacious drugs are urgently needed to treat all susceptible populations with cryptosporidiosis. Unlike other apicomplexans, Cryptosporidium parvum lacks the tricarboxylic acid cycle and the oxidative phosphorylation steps, making it solely dependent on glycolysis for metabolic energy production. We have previously reported that individual inhibitors of two unique glycolytic enzymes, the plant-like pyruvate kinase (CpPyK) and the bacterial-type lactate dehydrogenase (CpLDH), are effective against C. parvum , both in vitro and in vivo . Herein, we have derived combinations of CpPyK and CpLDH inhibitors with strong synergistic effects against the growth and survival of C. parvum , both in vitro and in an infection mouse model. In infected immunocompromised mice, compound combinations of NSC303244 + NSC158011 and NSC252172 + NSC158011 depicted enhanced efficacy against C. parvum reproduction and ameliorated intestinal lesions of cryptosporidiosis at doses fourfold lower than the total effective doses of individual compounds. Importantly, unlike individual compounds, NSC303244 + NSC158011 combination was effective in clearing the infection completely without relapse in immunocompromised mice. Collectively, our study has unveiled compound combinations that simultaneously block two essential catalytic steps for metabolic energy production in C. parvum to achieve improved efficacy against the parasite. These combinations are, therefore, lead compounds for the development of a new generation of efficacious anti-cryptosporidial drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathobiology, College of Veterinary Medicine, University of Illinois Urbana-Champaign , Urbana, Illinois, USA.
ORCID-Profile: Shahbaz M Khan, William H Witola
Förderung
- U.S. Department of Agriculture
Zitieren
APA
Khan, S. M., Bajwa, M. R., Lahar, R. Y., & Witola, W. H. (2023). Combination of inhibitors for two glycolytic enzymes portrays high synergistic efficacy against Cryptosporidium parvum. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00569-23
Vancouver
Khan SM, Bajwa MR, Lahar RY, Witola WH. Combination of inhibitors for two glycolytic enzymes portrays high synergistic efficacy against Cryptosporidium parvum. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.00569-23
BibTeX
@article{Khan2023,
author = {Khan, Shahbaz M and Bajwa, Muhammad Rashid and Lahar, Rachael Y and Witola, William H},
title = {Combination of inhibitors for two glycolytic enzymes portrays high synergistic efficacy against Cryptosporidium parvum},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2023},
doi = {10.1128/aac.00569-23}
}
EUVIMED